Advertisement

International Journal of Hematology

, Volume 108, Issue 5, pp 485–490 | Cite as

Transfusion requirements and 30-day mortality predictors for adult hemophagocytic lymphohistiocytosis

  • Zaher K. Otrock
  • Brenda J. Grossman
  • Charles S. Eby
Original Article
  • 107 Downloads

Abstract

Hemophagocytic lymphohistiocytosis (HLH) is a rare clinical syndrome characterized by an uncontrolled hyper-inflammatory response. We assessed the transfusion requirements and predictors of 30-day mortality for adult HLH patients. We identified all adult patients with a diagnosis of HLH at a large academic hospital from October 2003 through February 2017. We extracted patients’ clinical and laboratory data, including transfusion requirements, from their medical records. One-hundred sixteen patients were identified. Their median age was 48 years (range 18–82); 72(62%) were male. Median duration of hospital stay was 19 days (range 1–89 days). At 30 days from admission, 81(70%) patients were alive. Death was attributed to sepsis in 21 patients, lymphoma in six, bleeding in four, GVHD in one, liver failure in one, metastatic solid tumor in one, and unknown in one. Transfusion requirements at 30 days from admission were as follows: RBC, 86% of patients, median 6 units (range 1–58); platelets, 74% of patients, median 6 units (1–67); plasma, 40% of patients, median 4 units (1–56). Renal failure (OR = 4.39; P = 0.008) and hypofibrinogenemia (OR = 4.07; P = 0.009) correlated with 30-day mortality. The transfusion requirements for adult HLH patients were high. Our study indicated that renal insufficiency and hypofibrinogenemia are predictors of early death in adult HLH.

Keywords

Hemophagocytic lymphohistiocytosis Adult Renal failure Hypofibrinogenemia Transfusion 30-day mortality 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    George MR. Hemophagocytic lymphohistiocytosis: review of etiologies and management. J Blood Med. 2014;5:69–86.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Henter JI, Horne A, Arico M, Egeler RM, Filipovich AH, Imashuku S, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48:124–31.CrossRefPubMedGoogle Scholar
  3. 3.
    Janka GE. Familial and acquired hemophagocytic lymphohistiocytosis. Annu Rev Med. 2012;63:233–46.CrossRefPubMedGoogle Scholar
  4. 4.
    Ho C, Yao X, Tian L, Li FY, Podoltsev N, Xu ML. Marrow assessment for hemophagocytic lymphohistiocytosis demonstrates poor correlation with disease probability. Am J Clin Pathol. 2014;141:62–71.CrossRefPubMedGoogle Scholar
  5. 5.
    Gupta A, Tyrrell P, Valani R, Benseler S, Weitzman S, Abdelhaleem M. The role of the initial bone marrow aspirate in the diagnosis of hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2008;51:402–4.CrossRefPubMedGoogle Scholar
  6. 6.
    Grom AA, Mellins ED. Macrophage activation syndrome: advances towards understanding pathogenesis. Curr Opin Rheumatol. 2010;22:561–6.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Lykens JE, Terrell CE, Zoller EE, Risma K, Jordan MB. Perforin is a critical physiologic regulator of T-cell activation. Blood. 2011;118:618–26.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Naneh O, Avcin T, Bedina Zavec A. Perforin and human diseases. Subcell Biochem. 2014;80:221–39.CrossRefPubMedGoogle Scholar
  9. 9.
    Freeman HR, Ramanan AV. Review of haemophagocytic lymphohistiocytosis. Arch Dis Child. 2011;96:688–93.CrossRefPubMedGoogle Scholar
  10. 10.
    Otrock ZK, Eby CS. Clinical characteristics, prognostic factors, and outcomes of adult patients with hemophagocytic lymphohistiocytosis. Am J Hematol. 2015;90:220–4.CrossRefPubMedGoogle Scholar
  11. 11.
    Weaver LK, Behrens EM. Hyperinflammation, rather than hemophagocytosis, is the common link between macrophage activation syndrome and hemophagocytic lymphohistiocytosis. Curr Opin Rheumatol. 2014;26:562–9.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Milner JD, Orekov T, Ward JM, Cheng L, Torres-Velez F, Junttila I, et al. Sustained IL-4 exposure leads to a novel pathway for hemophagocytosis, inflammation, and tissue macrophage accumulation. Blood. 2010;116:2476–83.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Canna SW, Behrens EM. Making sense of the cytokine storm: a conceptual framework for understanding, diagnosing, and treating hemophagocytic syndromes. Pediatr Clin North Am. 2012;59:329–44.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Henter JI, Elinder G, Soder O, Ost A. Incidence in Sweden and clinical features of familial hemophagocytic lymphohistiocytosis. Acta Paediatr Scand. 1991;80:428–35.CrossRefPubMedGoogle Scholar
  15. 15.
    Hayden A, Park S, Giustini D, Lee AY, Chen LY. Hemophagocytic syndromes (HPSs) including hemophagocytic lymphohistiocytosis (HLH) in adults: a systematic scoping review. Blood Rev. 2016;30:411–20.CrossRefPubMedGoogle Scholar
  16. 16.
    Janka G. Hemophagocytic lymphohistiocytosis: when the immune system runs amok. Klin Padiatr. 2009;221:278–85.CrossRefPubMedGoogle Scholar
  17. 17.
    Raschke RA, Garcia-Orr R. Hemophagocytic lymphohistiocytosis: a potentially underrecognized association with systemic inflammatory response syndrome, severe sepsis, and septic shock in adults. Chest. 2011;140:933–8.CrossRefPubMedGoogle Scholar
  18. 18.
    Padhi S, Varghese RG, Ramdas A, Phansalkar MD, Sarangi R. Hemophagocytic lymphohistiocytosis: critical reappraisal of a potentially under-recognized condition. Front Med. 2013;7:492–8.CrossRefPubMedGoogle Scholar
  19. 19.
    Migdady Y, Weiner H, Lau E, Martin BA, Jeng MR, Oak J. Transfusion dependence is common in adults with hemophagocytic lymphohistiocytosis (HLH) and is associated with EBV viremia. Blood. 2017;130(Suppl 1):3737.Google Scholar
  20. 20.
    Palazzi DL, McClain KL, Kaplan SL. Hemophagocytic syndrome in children: an important diagnostic consideration in fever of unknown origin. Clin Infect Dis. 2003;36:306–12.CrossRefPubMedGoogle Scholar
  21. 21.
    Ramos-Casals M, Brito-Zeron P, Lopez-Guillermo A, Khamashta MA, Bosch X. Adult haemophagocytic syndrome. Lancet. 2014;383:1503–16.CrossRefPubMedGoogle Scholar
  22. 22.
    Chapman CE, Stainsby D, Jones H, Love E, Massey E, Win N, et al, Serious Hazards of Transfusion Steering Group. Ten years of hemovigilance reports of transfusion-related acute lung injury in the United Kingdom and the impact of preferential use of male donor plasma. Transfusion. 2009;49:440–52.CrossRefPubMedGoogle Scholar
  23. 23.
    Popovsky MA. Transfusion and the lung: circulatory overload and acute lung injury. Vox Sang. 2004;87:62–5.CrossRefPubMedGoogle Scholar
  24. 24.
    Pandey S, Vyas GN. Adverse effects of plasma transfusion. Transfusion. 2012;52:65S–79S.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Ranucci M, Pazzaglia A, Bianchini C, Bozzetti G, Isgrò G. Body size, gender, and transfusions as determinants of outcome after coronary operations. Ann Thorac Surg. 2008;85:481–6.CrossRefPubMedGoogle Scholar
  26. 26.
    Bilgin YM, van de Watering LM, Versteegh MI, van Oers MH, Vamvakas EC, Brand A. Postoperative complications associated with transfusion of platelets and plasma in cardiac surgery. Transfusion. 2011;51:2603–10.CrossRefPubMedGoogle Scholar
  27. 27.
    Camus M, Jensen DM, Kovacs TO, Jensen ME, Markovic D, Gornbein J. Independent risk factors of 30-day outcomes in 1264 patients with peptic ulcer bleeding in the USA: large ulcers do worse. Aliment Pharmacol Ther. 2016;43:1080–9.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Cohen JA, Alan N, Seicean A, Weil RJ. Risk associated with perioperative red blood cell transfusion in cranial surgery. Neurosurg Rev. 2017;40:633–42.CrossRefPubMedGoogle Scholar
  29. 29.
    Parikh SA, Kapoor P, Letendre L, Kumar S, Wolanskyj AP. Prognostic factors and outcomes of adults with hemophagocytic lymphohistiocytosis. Mayo Clin Proc. 2014;89:484–92.CrossRefPubMedGoogle Scholar
  30. 30.
    Arca M, Fardet L, Galicier L, Rivière S, Marzac C, Aumont C, et al. Prognostic factors of early death in a cohort of 162 adult haemophagocytic syndrome: impact of triggering disease and early treatment with etoposide. Br J Haematol. 2015;168:63–8.CrossRefPubMedGoogle Scholar
  31. 31.
    Aulagnon F, Lapidus N, Canet E, Galicier L, Boutboul D, Peraldi MN, et al. Acute kidney injury in adults with hemophagocytic lymphohistiocytosis. Am J Kidney Dis. 2015;65:851–9.CrossRefPubMedGoogle Scholar
  32. 32.
    Li F, Yang Y, Jin F, Dehoedt C, Rao J, Zhou Y, et al. Clinical characteristics and prognostic factors of adult hemophagocytic syndrome patients: a retrospective study of increasing awareness of a disease from a single-center in China. Orphanet J Rare Dis. 2015;10:20.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Wang YR, Qiu YN, Bai Y, Wang XF. A retrospective analysis of 56 children with hemophagocytic lymphohistiocytosis. J Blood Med. 2016;7:227–31.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2018

Authors and Affiliations

  • Zaher K. Otrock
    • 1
  • Brenda J. Grossman
    • 2
  • Charles S. Eby
    • 2
  1. 1.Department of Pathology and Laboratory MedicineHenry Ford HospitalDetroitUSA
  2. 2.Department of Pathology and ImmunologyBarnes-Jewish Hospital, Washington UniversitySt LouisUSA

Personalised recommendations